TIME Is a Great Healer—Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes
暂无分享,去创建一个
[1] E. de Azambuja,et al. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? , 2020, ESMO Open.
[2] C. Porta,et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial , 2020, Journal for ImmunoTherapy of Cancer.
[3] Q. Hao,et al. CCL2/CCR2 signaling in cancer pathogenesis , 2020, Cell Communication and Signaling.
[4] Scott N. Mueller,et al. Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling , 2020, Nature Cell Biology.
[5] D. Berry,et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. , 2020, JAMA oncology.
[6] Z. Modrušan,et al. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. , 2020, Immunity.
[7] C. Evans,et al. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis , 2020, Frontiers in Immunology.
[8] Tonje G. Lien,et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment , 2019, Nature Communications.
[9] E. Winer,et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[10] Xuelei Ma,et al. Myeloid-Derived Suppressor Cells Promote Metastasis in Breast Cancer After the Stress of Operative Removal of the Primary Cancer , 2019, Front. Oncol..
[11] X. Zhang,et al. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms , 2019, Nature Cell Biology.
[12] L. Wessels,et al. Loss of p53 triggers Wnt-dependent systemic inflammation to drive breast cancer metastasis , 2019, Nature.
[13] A. Viola,et al. The Metabolic Signature of Macrophage Responses , 2019, Front. Immunol..
[14] R. Fields,et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies , 2019, Science Translational Medicine.
[15] M. Alexander,et al. The role of macrophages in the resolution of inflammation. , 2019, The Journal of clinical investigation.
[16] M. Ahn,et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Jeffrey T. Chang,et al. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). , 2019, Journal of Clinical Oncology.
[18] T. Flotte,et al. Quantitative assessment of tumor-infiltrating neutrophils to predict immunotherapy responses in metastatic melanoma. , 2019, Journal of Clinical Oncology.
[19] Benjamin Haibe-Kains,et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers , 2019, The Journal of clinical investigation.
[20] S. O'Reilly,et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.
[21] M. Salmi,et al. Fetal-derived macrophages dominate in adult mammary glands , 2019, Nature Communications.
[22] E. D. de Vries,et al. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.
[23] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[24] Y. Zou,et al. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy , 2018, PloS one.
[25] X. Zhang,et al. Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target? , 2018, Front. Immunol..
[26] J. Pollard,et al. A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.
[27] N. Bercovici,et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.
[28] A. Kriegstein,et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment , 2017, Genome Biology.
[29] Gabriela Silva,et al. Notch-out for breast cancer therapies. , 2017, New biotechnology.
[30] Dafeng Yang,et al. SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells. , 2017, Cancer research.
[31] Emily A Foley,et al. Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents , 2017, Cell reports.
[32] D. Edwards,et al. Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation , 2016, Nature Cell Biology.
[33] R. Muschel,et al. Targeting the CCL2-CCR2 signaling axis in cancer metastasis , 2016, Oncotarget.
[34] K. Hunter,et al. CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. , 2015, Cancer research.
[35] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[36] L. van de Laar,et al. A Hitchhiker’s Guide to Myeloid Cell Subsets: Practical Implementation of a Novel Mononuclear Phagocyte Classification System , 2015, Front. Immunol..
[37] P. Kronqvist,et al. Human breast cancer cells educate macrophages toward the M2 activation status , 2015, Breast Cancer Research.
[38] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[39] Helena Jernström,et al. Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients , 2015, PloS one.
[40] Michael A. Hollingsworth,et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.
[41] Abhishek K. Jha,et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. , 2015, Immunity.
[42] V. Seewaldt,et al. Triple-negative breast cancer in African-American women: disparities versus biology , 2015, Nature Reviews Cancer.
[43] B. Neyns,et al. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model , 2015, Oncoimmunology.
[44] Charles J. Vaske,et al. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53 , 2014, Molecular Cancer Research.
[45] Zhongyu Yuan,et al. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis , 2014, OncoTargets and therapy.
[46] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] A. Børresen-Dale,et al. Triple-negative breast cancer and the need for new therapeutic targets. , 2013, The American journal of pathology.
[48] J. Markowitz,et al. Myeloid-derived suppressor cells in breast cancer , 2013, Breast Cancer Research and Treatment.
[49] M. Clarke,et al. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors , 2013, Intravital.
[50] A. Mildner,et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. , 2013, Immunity.
[51] S. Aiba,et al. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth , 2012, Oncoimmunology.
[52] V. Polláková,et al. Cyclophosphamide-induced Myeloid-derived Suppressor Cell Population Is Immunosuppressive But Not Identical to Myeloid-derived Suppressor Cells Induced By Growing TC-1 Tumors , 2012, Journal of immunotherapy.
[53] J. Pollard,et al. A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells , 2012, Science.
[54] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[55] Jason I. Herschkowitz,et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells , 2011, Proceedings of the National Academy of Sciences.
[56] M. Ewen,et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. , 2011, Cancer cell.
[57] F. Ginhoux,et al. Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.
[58] J. Vieweg,et al. Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine , 2010, Cancer Immunology, Immunotherapy.
[59] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[60] R. Figlin,et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.
[61] M. Manns,et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.
[62] S. Kaufmann. Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff , 2008, Nature Immunology.
[63] C. Watson,et al. Mammary development in the embryo and adult: a journey of morphogenesis and commitment , 2008, Development.
[64] J. Pollard,et al. Tumor-associated macrophages press the angiogenic switch in breast cancer. , 2007, Cancer research.
[65] P. Rodriguez,et al. Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[66] Alberto Mantovani,et al. Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.
[67] Jeffrey W Pollard,et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.
[68] F. Kittrell,et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[69] Andrew V. Nguyen,et al. Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.
[70] S. Ostrand-Rosenberg,et al. Mouse 4T1 Breast Tumor Model , 2000, Current protocols in immunology.
[71] A. Dove. CD18 trials disappoint again , 2000, Nature Biotechnology.
[72] D. Greiner,et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.
[73] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.
[74] L. Emens,et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. , 2019, The New England journal of medicine.
[75] S. Singhal,et al. Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. , 2017, Cancer discovery.
[76] X. Zhang,et al. Repurposing Antiestrogens for Tumor Immunotherapy. , 2017, Cancer discovery.
[77] L. Chin,et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.
[78] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .